Best of the Week
Most Popular
1.What Happened to the Stock Market Crash Experts Were Predicting - Sol_Palha
2.London Housing Market Property Bubble Vulnerable To Crash - GoldCore
3.The Plan to Control ALL Your Money is Now at Advanced Stage
4.Why Gold Is Set For An Epic Rally This Spring - James Burgess
5.MR ROBOT NHS Cyber Attack Hack - Why Israel, NSA, CIA and GCHQ are Culpable - Nadeem_Walayat
6.Emmanuel Macron and Banking Elite Win French Presidential Election 2017 - Nadeem_Walayat
7.Trend Lines Met, Technical's are Set - US Dollar is Ready to Rally (Elliott Wave Analysis) - Enda_Glynn
8.The Student Debt Servitude Sham - Gordon_T_Long
9.Czar Trump Fires Comey, Terminates Deep State FBI, CIA Director Next? - Nadeem_Walayat
10.UK Local Elections 2017 - Labour Blood Bath, UKIP Death, Tory June 8th Landslide - Nadeem_Walayat
Last 7 days
SPX/NDX/NAZ Hit New All-time Highs - 27th May 17
GBPUSD Top in Place, GOLD Price Ready to Rocket? - 27th May 17
Silver Mining Stocks Fundamentals - 27th May 17
BBC Newsnight Falls for FAKE POLLS, Opinion Pollsters Illusion for Mainstream Media to Sell - 27th May 17
UK Local Election Results Forecast for General Election 2017 - 26th May 17
Stock Market & Crude Oil Forecast! - 26th May 17
Opinion Pollsters UK General Election Seats Forecasts 2017 - 26th May 17
Bitcoin and AltCoins Crypto Price Correction - 26th May 17
Bearish Head and Shoulders in EURUSD? - 26th May 17
SELL US Stocks - Massive Market CRASH WARNING! - 26th May 17
EURGBP: A Picture of Elliott Wave Precision - 26th May 17
Credit Downgrades May Prompt Stock Market Capital Shift - 26th May 17
Rosenstein and Mueller: the Regime Change Tag-Team - 25th May 17
Stock Market Top - Are We There Yet? - 25th May 17
Should I Invest My Fortune in Gold? Inaugural Lecture by Dr Brian Lucey - 25th May 17
USD/CAD Continues Decline - 25th May 17
Bitcoin Price Goes Loco! Surges through $2,500 Despite Unclear Fork Issues - 25th May 17
The US-Saudi Arms Deal - Sordid Saudi Signals - 25th May 17
The No.1 Commodity Play In The World Today - 24th May 17
Marks and Spencer Profits Collapse, Latest Retailer Hit by Brexit Inflation Tsunami 2017 - 24th May 17
Why Online Trading Platforms Are Useful for Everyone - 24th May 17
The Stock Market Will Tank Hard - 24th May 17
It’s Better to Buy Gold & Silver When It DOESN’T Feel Good - 24th May 17
Global Warming - Saving Us From Us - 24th May 17
Stock Market Forecast for Next 3 Months - Video - 23rd May 17
Shale Oil & Gas Production Costs Spiral Higher As Monstrous Decline Rates Eat Into Cash Flows - 23rd May 17
The Only Metal Trump Wants More Than Gold - 23rd May 17
America's Southern Heritage is a Threat to the Deep State - 23rd May 17
Manchester Bombing - ISIS Islamic Terrorist Attack Attempt to Influence BrExit Election - 23rd May 17
What an America First Trade Policy Could Mean for the US Dollar - 22nd May 17
Gold and Sillver Markets - Silver Price Sharp Selloff - 22nd May - 22nd May 17
Stock Market Volatile C-Wave - 22nd May 17
Stock Market Trend Forecast and Fear Trading - 22nd May 17
US Dollar Cycle : Deep Dive - 21st May 17
Bitcoin Breaks the $2,000 Mark as Cryptocurrencies Continue to Explode Higher - 21st May 17
Stocks, Commodities and Gold Multi-Market Status - 21st May 17
Stock Market Day Trading Strategies and Brief 20th May 2017 - 21st May 17
DOW Needs to Rally Big or Correction is Next - 20th May 17
EURUSD reaches DO or DIE moment! - 20th May 17
How to Get FREE Walkers Crisps Multi-packs! £5 to £28k Pay Packet Promo - 20th May 17

Market Oracle FREE Newsletter

Why 95% of Traders Fail

Could This Be The Biggest Biotech Breakthrough Of The Decade?

Companies / BioTech Mar 13, 2017 - 06:25 AM GMT

By: OilPrice_Com

Companies A little-known, visionary biotech company is gearing up to release a potentially ground-breaking medical device that could help prevent strokes. It could help save six million lives a year—or a life every 4 minutes. 

The unique new technology is the Carotid Stenotic Scan (CSS), by CVR Medical, and its futuristic system is designed to sense the leading indicator of strokes in only 2 minutes, and at a cost that will make it affordable and accessible to everyone.


CVR Medical (TSX:CVM.V ; OTC:CRRVF) is ready to burst out of the gate directly into a massive market. Here’s why:

  • This is unprecedented: Pre-stroke intervention has never before been affordable and accessible
  • It’s not invasive and preliminary tests demonstrate that in most cases it takes only 2 minutes
  • The patented technology is positioned to own this huge market segment
  • A CSS unit costs roughly $49,000, while current technology costs up to $2.5 million, making it economically out of reach
  • Over 230,000 medical facilities in the U.S. alone could potentially want the device, and globally the demand could be huge
  • The visionary team has invested $23 million in development and is expecting preliminary clinical results any day now

For the First Time in History: An Affordable Solution to a Multi-Billion-Dollar Problem

Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. In the U.S. alone, nearly 800,000 people suffer from a stroke annually.

Currently, one out of every 20 deaths in America is caused by stroke, making this one of the most pressing medical problems of our time.

Until now, there has been no cost-effective way to screen for the leading indicator of Ischemic strokes, which cost the U.S. government alone over 30 billion dollars a year in healthcare expenses.

CVR Medical (TSX:CVM.V ; OTC:CRRVF), the company behind this medical device, has been quietly developing the technology for 10 years—and now it’s ready for its life-changing debut.  

The company reckons that its diagnostic tool could not only help the millions of lives affected by Ischemia, the leading cause of stroke, but could also significantly reduce the tragic debilitation some 5 million people suffer every year because of stroke.  

CVR’s early detection technology does not depend on the user for accuracy and provides results in only 2 minutes.  

When it takes only 2 minutes to detect the leading indicator of stroke with a device that costs only $49,000 compared to up to $2.5 million for current technology—the market potential is phenomenal.

CVR’s technology is positioned to own this market segment.

A low-cost, low maintenance pre-stroke medical intervention could benefit the entire society. Ischemia detection technology could save the U.S. government up to $34 billion a year, which is how much the Centers for Disease Control (CDC) say strokes cost the U.S. annually.

According to the CDC, early action is urgent for survival, and only 38 percent of stroke sufferers even recognize they are having a stroke in time to receive effective emergency intervention.

Amid this urgency, the market is massive—and it’s hungry for a breakthrough.

In the U.S. alone, the market includes 234,615 primary care offices, specialist offices, hospitals and clinics—all of which would benefit from CVR’s ground-breaking, affordable, non-invasive and easy-to-use technology to help the millions of people who suffer from carotid artery disease, or Ischemia. 

If these facilities bought just one CSS pre-stroke intervention system, we would be looking at  billions in revenue. CVR expects to fully penetrate not only the domestic market, but the gargantuan global market.

Because the all-in costs are less than half the sale costs, the company is expecting a very quick and lucrative head start.

Brilliant Technology, Visionary Developers

CSS is a screening tool that is designed to detect and measure carotid arterial stenosis to identify patients at risk from Ischemic Stroke.

CSS technology makes a connection between fluid flow and sub-sonic frequencies to detect arterial disease or blockage.

Blood flowing through the carotid arteries produces wave patterns which are shaped and altered by the presence of irregularities on the inner artery walls.

CVR’s advanced technology is designed to capture these wave patterns and analyze them mathematically with patented algorithms.

With a quiet modesty and professionalism rare in the biotech industry, the dream team behind the technology has not only developed something that could radically change how we deal with the number 2 cause of death in the U.S., but it’s also expertly leveraged intellectual property, market sentiment and strategic partnerships.

CVR Medical (TSX:CVM.V ; OTC:CRRVF) recently teamed up with Hitachi (NYSE:HIT), which will develop and create the processing unit to operate the Carotid Stenotic Scan device, enabling CVR Medical to be able to interpret the sub-sonic and infrasonic sound waves it collects in real time.

Led by Chairman, CEO and President Peter Bakema—with an impressive 30-year track record in business development, since its inception, CVR has brought on some of the most respected medical professionals in the industry.

  • Tony Robinson, COO and Executive Vice-President has been with CVR for 8 years and has extensive domestic and global healthcare experience.  
  • Michael Rhodes, VP of Quality Systems, is a former VP for Quality for HSBC and Motorola. He has 20 years of experience in multiple markets.
  • Dr. W. Douglas Weaver, a member of the BOD Scientific Advisory Board, is the former president of the American College of Cardiology and the former VP and System Medical Director of Heart and Vascular Services at Henry Ford Health System. His over 330 publications related to drug and device discovery have been some of the most influential in our time.

Together, they are on a trajectory which will revolutionize healthcare by offering easily accessible, affordable early detection for a potentially massive market share at a very critical time in our healthcare story.

Like the X-ray, invented in 1895 and enriching medical investors with wild implications for clinical practice, CVR’s early stroke detection device is poised to spark changes far beyond the widespread implementation of the device itself. Indeed, the CSS is only the first phase of CVR’s plans to contribute in a very positive way to medical diagnostics.

Cashed-Up, Patented, and Ready to Take the Market by Storm

CVR (TSX:CVM.V ; OTC:CRRVF) has invested $23 million in this technology, with early stage clinical trials complete and now headed toward pivotal trials, eyeing the potential for immediate profitability once FDA market clearance is obtained.

This means there’s only a short window of opportunity between market and profitability.

The critical timeframe is now: The release of a preliminary clinical report is pending any day, and then the full clinical report will follow in 4-8 weeks. Once that happens, the next step is FDA submission, and if successful, delivery to the market.

The team has already lined up manufacturing and components, so once the clinical reports are in, and the FDA hurdle is cleared, it’s breakout time.

For biotech in general, 2017 will be the critical breakout year. For CVR Medical’s patented pre-stroke intervention system, it will be the debut of an amazing new technology that promises to capture the lion’s share of a multi-billion-dollar market that could hit out hard at one of the most pressing medical issues of our time.  

By. Charles Kennedy of Oilprice.com

Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Oilprice.com only and are subject to change without notice. Oilprice.com assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. All content contained herein is subject to the terms and conditions set forth in the original article posted on Oilprice.com and subject to the terms and conditions therein.

OilPrice.com Archive

© 2005-2016 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife